<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30239026</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1539-6924</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Risk analysis : an official publication of the Society for Risk Analysis</Title><ISOAbbreviation>Risk Anal</ISOAbbreviation></Journal><ArticleTitle>Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan.</ArticleTitle><Pagination><StartPage>389</StartPage><EndPage>401</EndPage><MedlinePgn>389-401</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/risa.13194</ELocationID><Abstract><AbstractText>Only Pakistan and Afghanistan reported any polio cases caused by serotype 1 wild polioviruses (WPV1s) in 2017. With the dwindling cases in both countries and pressure to finish eradication with the least possible resources, a danger exists of inappropriate prioritization of efforts between the two countries and insufficient investment in the two countries to finish the job. We used an existing differential-equation-based poliovirus transmission and oral poliovirus (OPV) evolution model to simulate a proactive strategy to stop transmission, and different hypothetical reactive strategies that adapt the quality of supplemental immunization activities (SIAs) in response to observed polio cases in Pakistan and Afghanistan. To account for the delay in perception and adaptation, we related the coverage of the SIAs in high-risk, undervaccinated subpopulations to the perceived (i.e., smoothed) polio incidence. Continuation of the current frequency and quality of SIAs remains insufficient to eradicate WPV1 in Pakistan and Afghanistan. Proactive strategies that significantly improve and sustain SIA quality lead to WPV1 eradication and the prevention of circulating vaccine-derived poliovirus (cVDPV) outbreaks. Reactive vaccination efforts that adapt moderately quickly and independently to changes in polio incidence in each country may succeed in WPV1 interruption after several cycles of outbreaks, or may interrupt WPV1 transmission in one country but subsequently import WPV1 from the other country or enable the emergence of cVDPV outbreaks. Reactive vaccination efforts that adapt independently and either more rapidly or more slowly to changes in polio incidence in each country may similarly fail to interrupt WPV1 transmission and result in oscillations of the incidence. Reactive strategies that divert resources to the country of highest priority may lead to alternating large outbreaks. Achieving WPV1 eradication and subsequent successful OPV cessation in Pakistan and Afghanistan requires proactive and sustained efforts to improve vaccination intensity in under-vaccinated subpopulations while maintaining high population immunity elsewhere.</AbstractText><CopyrightInformation>&#xa9; 2018 Society for Risk Analysis.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duintjer Tebbens</LastName><ForeName>Radboud J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Columbus, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U2R GH001913</GrantID><Acronym>GH</Acronym><Agency>CGH CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1U2RGH001913-01</GrantID><Acronym>GH</Acronym><Agency>CGH CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Risk Anal</MedlineTA><NlmUniqueID>8109978</NlmUniqueID><ISSNLinking>0272-4332</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000346" MajorTopicYN="N" Type="Geographic">Afghanistan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010154" MajorTopicYN="N" Type="Geographic">Pakistan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015397" MajorTopicYN="N">Program Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dynamic modeling</Keyword><Keyword MajorTopicYN="N">polio eradication</Keyword><Keyword MajorTopicYN="N">risk management</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30239026</ArticleId><ArticleId IdType="mid">NIHMS1665825</ArticleId><ArticleId IdType="pmc">PMC7857157</ArticleId><ArticleId IdType="doi">10.1111/risa.13194</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alam MM, Sharif S, Shaukat S, Angez M, Khurshid A, Rehman L, &amp; Zaidi SS (2016). Genomic surveillance elucidates persistent wild poliovirus transmission during 2013&#x2013;2015 in major reservoir areas of Pakistan. Clin Infect Dis, 62(2), 190&#x2013;198. doi:10.1093/cid/civ831</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ831</ArticleId><ArticleId IdType="pubmed">26417032</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyesh-Melnick M, Melnick JL, Rawls WE, Wimberly I, Barrera Ora J, Ben-Porath E, &amp; Rennick V (1967). Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. American Journal of Epidemiology, 86(1), 112&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">4378110</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake IM, Martin R, Goel A, Khetsuriani N, Everts J, Wolff C, &#x2026; Grassly NC (2014). The role of older children and adults in wild poliovirus transmission. Proc Natl Acad Sci U S A, 111(29), 10604&#x2013;10609. doi:10.1073/pnas.1323688111</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1323688111</ArticleId><ArticleId IdType="pmc">PMC4115498</ArticleId><ArticleId IdType="pubmed">25002465</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, &amp; Thompson KM (2016). Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. Journal of Vaccines and Vaccination, 7(5), 340. doi:10.4172/2157-7560.1000340</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2157-7560.1000340</ArticleId><ArticleId IdType="pmc">PMC5497833</ArticleId><ArticleId IdType="pubmed">28690915</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Kalkowska DA, Wassilak SGF, Pallansch MA, Cochi SL, &amp; Thompson KM (2014). The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis, 14, 45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918103</ArticleId><ArticleId IdType="pubmed">24472313</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, &#x2026; Thompson KM (2013a). Expert review on poliovirus immunity and transmission. Risk Analysis, 33(4), 544&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896540</ArticleId><ArticleId IdType="pubmed">22804479</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, &#x2026; Thompson KM (2013b). Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Analysis, 33(4), 606&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7890644</ArticleId><ArticleId IdType="pubmed">23550968</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, &#x2026; Thompson KM (2018). Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations. Risk Analysis, 38(8), 1701&#x2013;1717. doi:10.1111/risa.12962</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.12962</ArticleId><ArticleId IdType="pmc">PMC7879700</ArticleId><ArticleId IdType="pubmed">29314143</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, &#x2026; Thompson KM (2011). Economic analysis of the Global Polio Eradication Initiative. Vaccine, 29(2), 334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">21029809</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, &amp; Thompson KM (2015). An economic analysis of poliovirus risk management policy options for 2013&#x2013;2052. BMC Infect Dis, 15, 389. doi:10.1186/s12879-015-1113-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1113-7</ArticleId><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, &amp; Thompson KM (2013). Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Analysis, 23(4), 703&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">23521018</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, &#x2026; Thompson KM (2013). Review: Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Analysis, 23(4), 680&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7890645</ArticleId><ArticleId IdType="pubmed">23470192</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL &amp; Thompson KM (2016). Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infectious Diseases 16:137, doi: 10.1186/s12879-016-1465-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-1465-7</ArticleId><ArticleId IdType="pmc">PMC4806487</ArticleId><ArticleId IdType="pubmed">27009272</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, &amp; Thompson KM (2009). Priority shifting and the dynamics of managing eradicable infectious disease. Management Science, 55(4), 650&#x2013;663.</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, &amp; Thompson KM (2014). Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. Journal of Infectious Diseases, 210(Suppl 1), S485&#x2013;S497.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316871</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, &amp; Thompson KM (2017a). Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential OPV cessation risk management strategy. Epidemiology and Infection, 145(2), 217&#x2013;226. doi:10.1017/S0950268816002302</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268816002302</ArticleId><ArticleId IdType="pmc">PMC5197684</ArticleId><ArticleId IdType="pubmed">27760579</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, &amp; Thompson KM (2017b). Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. Medical Decision Making Policy &amp; Practice, 2, 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6124926</ArticleId><ArticleId IdType="pubmed">30288417</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichner M, &amp; Dietz K (1996). Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? American Journal of Epidemiology, 143(8), 816&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">8610692</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenner F, Henderson DA, Arita I, Jezek Z, &amp; Ladnyi ID (1988). Smallpox and its eradication. Geneva, Switzerland: World Health Organization.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. (2015, September 20, 2015). Global eradication of wild poliovirus type 2 declared. Retrieved from http://www.polioeradication.org/mediaroom/newsstories/Global-eradication-of-wild-poliovirus-type-2-declared/tabid/526/news/1289/Default.aspx</Citation></Reference><Reference><Citation>Kahn AW, &amp; Taylor-Robinson AW (2017). Major shift in national health policy towards poliomyelitis in Pakistan reaps rewards. Infection, Disease &amp; Health, 22(3), 153&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">31862092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SGF, &#x2026; Thompson KM (2015). Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. Journal of Infectious Diseases, 211(11), 1800&#x2013;1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887763</ArticleId><ArticleId IdType="pubmed">25505296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, &amp; Thompson KM (2015). Modeling undetected live poliovirus circulation after apparent interruption of transmission: Implications for surveillance and vaccination. BMC Infect Dis, 15(66), 1. doi:10.1186/s12879-015-0791-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-0791-5</ArticleId><ArticleId IdType="pmc">PMC4344758</ArticleId><ArticleId IdType="pubmed">25886823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, &amp; Thompson KM (2018). Modeling undetected live poliovirus circulation after apparent interruption of transmission in Pakistan and Afghanistan. Risk Analysis, doi: 10.1111/risa.13214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13214</ArticleId><ArticleId IdType="pmc">PMC7842182</ArticleId><ArticleId IdType="pubmed">30296340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, &amp; Thompson KM (2014a). Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. Journal of Infectious Diseases, 210(Suppl 1), S412&#x2013;S423.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Duintjer Tebbens RJ, &amp; Thompson KM (2014b). Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. Journal of Infectious Diseases, 210(Suppl 1), S398&#x2013;S411.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Cochi SL, Jafari HS, Wassilak SG, Mast EE, Diop OM, &#x2026; Centers for Disease Control and Prevention (CDC). (2014). Possible eradication of wild poliovirus type 3--worldwide, 2012. Morbidity and Mortality Weekly Report, 63(45), 1031&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5779498</ArticleId><ArticleId IdType="pubmed">25393222</ArticleId></ArticleIdList></Reference><Reference><Citation>Library of Congress. (2008). Country profile: Afghanistan. Retrieved from https://www.loc.gov/rr/frd/cs/profiles/Afghanistan.pdf</Citation></Reference><Reference><Citation>Mach O, Tangermann RH, Wassilak SG, Singh S, &amp; Sutter RW (2014). Outbreaks of paralytic poliomyelitis during 1996&#x2013;2012: the changing epidemiology of a disease in the final stages of eradication. Journal of Infectious Diseases, 210(Suppl 1), S275&#x2013;S282. doi:10.1093/infdis/jit454</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit454</ArticleId><ArticleId IdType="pubmed">25316846</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay MA, Collett MS, Hincks JM, Oberste MS, Pallansch MA, Okayasu H, &#x2026; Dowdle WR (2014). Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. Journal of Infectious Diseases, 210(Suppl 1), S447&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316866</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer LD, Safdar RM, Ahmed J, Mahamud A, Khan MM, Gerber S, &#x2026; Chabot-Couture G (2017). Spatial model for risk prediction and sub-national prioritization to aid poliovirus eradication in Pakistan. BMC Med, 15(1), 180. doi:10.1186/s12916-017-0941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-017-0941-2</ArticleId><ArticleId IdType="pmc">PMC5635525</ArticleId><ArticleId IdType="pubmed">29017491</ArticleId></ArticleIdList></Reference><Reference><Citation>Molodecky NA, Blake IM, O&#x2019;Reilly KM, Wadood MZ, Safdar RM, Wesolowski A, &#x2026; Grassly NC (2017). Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis. PLoS Med, 14(6), e1002323. doi:10.1371/journal.pmed.1002323</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002323</ArticleId><ArticleId IdType="pmc">PMC5467805</ArticleId><ArticleId IdType="pubmed">28604777</ArticleId></ArticleIdList></Reference><Reference><Citation>Mushtaq A, Mehmood S, &amp; Hyder MZ (2017). A success story of Pakistan: The country at the verge of winning the battle against polio. Travel Med Infect Dis, 18, 81&#x2013;82. doi:10.1016/j.tmaid.2017.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2017.07.001</ArticleId><ArticleId IdType="pubmed">28687364</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N, &amp; Kew OM (2010). From emergence to eradication: the epidemiology of poliomyelitis deconstructed. American Journal of Epidemiology, 172(11), 1213&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2991634</ArticleId><ArticleId IdType="pubmed">20978089</ArticleId></ArticleIdList></Reference><Reference><Citation>Nnadi C, Damisa E, Esapa L, Braka F, Waziri N, Siddique A, &#x2026; Adamu U (2017). Continued endemic wild poliovirus transmission in security-compromised areas - Nigeria, 2016. MMWR Morb Mortal Wkly Rep, 66(7), 190&#x2013;193. doi:10.15585/mmwr.mm6607a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6607a2</ArticleId><ArticleId IdType="pmc">PMC5657850</ArticleId><ArticleId IdType="pubmed">28233765</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakistan Bureau of Statistics. (2017). Population by Mother Tongue. Retrieved from http://www.pbs.gov.pk/content/population-mother-tongue</Citation></Reference><Reference><Citation>Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. (2017). World Population Prospects. The 2017 revision. Volume I: Comprehensive tables (ESA/P/WP/248)
Retrieved from https://esa.un.org/unpd/wpp/Publications/Files/WPP2017_Volume-I_Comprehensive-Tables.pdf</Citation></Reference><Reference><Citation>Shirreff G, Wadood MZ, Vaz RG, Sutter RW, &amp; Grassly NC (2017). Estimated effect of inactivated poliovirus vaccine campaigns, Nigeria and Pakistan, January 2014-April 2016. Emerg Infect Dis, 23(2), 258&#x2013;263. doi:10.3201/eid2302.161210</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2302.161210</ArticleId><ArticleId IdType="pmc">PMC5324799</ArticleId><ArticleId IdType="pubmed">27861118</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterman J (2000). Business dynamics: Systems thinking and modeling for a complex world. Boston, MA: McGraw-Hill.</Citation></Reference><Reference><Citation>Sutter RW, Kew OM, Cochi SL, &amp; Aylward RB (2013). Poliovirus vaccine -- Live In Plotkin SA, Orenstein WA, &amp; Offit PA (Eds.), Vaccines (Sixth ed., pp. 598&#x2013;645). Philadelphia: Saunders Elsevier.</Citation></Reference><Reference><Citation>Thompson KM, &amp; Duintjer Tebbens RJ (2007). Eradication versus control for poliomyelitis: An economic analysis. Lancet, 369(9570), 1363&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448822</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Duintjer Tebbens RJ (2014). Modeling the dynamics of oral poliovirus vaccine cessation. Journal of Infectious Diseases, 210(Suppl 1), S475&#x2013;S484.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316870</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, &amp; Duintjer Tebbens RJ (2017). Lessons from the polio endgame: Overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. Journal of Infectious Diseases, 216(Suppl 1), S176&#x2013;S182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853387</ArticleId><ArticleId IdType="pubmed">28838194</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim J-H, &amp; Cochi SL (2013). Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Analysis, 33(4), 516&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7941951</ArticleId><ArticleId IdType="pubmed">23461599</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner BG, Behrend MR, Klein DJ, Upfill-Brown AM, Eckhoff PA, &amp; Hu H (2014). Quantifying the impact of expanded age group campaigns for polio eradication. PLoS One, 9(12), e113538. doi:10.1371/journal.pone.0113538</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0113538</ArticleId><ArticleId IdType="pmc">PMC4249973</ArticleId><ArticleId IdType="pubmed">25437014</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Assembly. (1988). Global eradication of poliomyelitis by the year 2000 (resolution 41.28) Geneva: World Health Organization.</Citation></Reference><Reference><Citation>World Health Organization. (2017). OPV cessation. Retrieved from http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/opv-cessation/</Citation></Reference><Reference><Citation>World Health Organization. (2018). Polio this week as of 3 January 2018. Retrieved from http://polioeradication.org/polio-today/polio-now/this-week/</Citation></Reference><Reference><Citation>World Health Organization Regional Office for the Eastern Mediterranean. (2015a). New polio vaccine introduced to accelerate polio eradication in Afghanistan. Retrieved from http://www.emro.who.int/pak/pakistan-news/introduces-ipv-in-routine-immunization.html</Citation></Reference><Reference><Citation>World Health Organization Regional Office for the Eastern Mediterranean. (2015b). Pakistan second endemic country to introduce IPV into routine immunization schedule. Retrieved from http://www.emro.who.int/pak/pakistan-news/introduces-ipv-in-routine-immunization.html</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>